Stay Informed

Global health R&D delivers forVirginia

Map
Virginia
Select a new state

US government investment in global health R&D has delivered

$874.5 million
to Virginia research institutions
9,700+ new jobs
for Virginia
Virginia

Neglected diseases in Virginia

Chikungunya cases
Chikungunya cases
93
Dengue cases
Dengue cases
129
HIV diagnoses
HIV diagnoses
8673
Malaria cases
Malaria cases
484
Tuberculosis cases
Tuberculosis cases
2081
West Nile cases
West Nile cases
92
Zika cases
Zika cases
118
Virginia's top USG-funded global health R&D institutions

Virginia's top USG-funded global health R&D institutions

Department of Defense (self-funding and other agency transfers)
$630.2 million
CONRAD
$145.8 million
Virginia Polytechnic Institute and State University (Virginia Tech)
$32.1 million
American Type Culture Collection
$27.6 million
University of Virginia
$21.5 million
US National Science Foundation
$9.3 million
Northrop Grumman Corporation
$3.6 million
Eastern Virginia Medical School
$2.6 million
US Civilian Research and Development Foundation (CRDF Global)
$545 thousand
University of Richmond
$500 thousand
James Madison University
$446 thousand
Ferrum College
$153 thousand
US Systems Research and Application Corporation (now part of CSRA)
$85 thousand
NETE Solutions
$8 thousand
Virginia industry in global health R&D

Virginia industry in global health R&D

Celgene
Location(s): Arlington
CSRA
Location(s): Falls Church
Cupron
Location(s): Richmond
Jericho Sciences
Location(s): Fairfax Station
Luna Innovations
Location(s): Roanoke
Merck & Co
Location(s): Elton
NETE Solutions
Location(s): McLean
Northrop Grumman
Location(s): Falls Church, Herndon
Parabon NanoLabs
Location(s): Reston
Thermal Gradient
Location(s): Richmond
Virongy
Location(s): Manassas

Virginia's top areas of global health R&D by USG funding

42.8%
HIV/AIDS
25.3%
Malaria
3.8%
Tuberculosis
9.9%
Diarrheal diseases
8.9%
Ebola/viral hemorrhagic fevers
4.5%
Neglected tropical diseases
Buruli ulcer
Dengue
Helminths
Kinetoplastids
Leprosy
4.8%
Other
Bacterial pneumonia & meningitis
Non-allocable
Salmonella infections
Global health R&D at work in Virginia
Global health R&D at work in Virginia

Many drugs used to treat HIV/AIDS have life-threatening side effects. One new, highly effective drug doesn’t, but it’s extremely expensive to produce. Virginia Commonwealth University is aiming to make it cheaper. Drugs with fewer side effects are important for long-term care of HIV/AIDS patients, who must take the drugs for life. The university has a proven track record for reinventing how drugs are made, resulting in cost-effective products that save lives.

Download PDF
Map
Select a new state
Footnotes
  • Methodology
  • USG global health R&D investment to state research institutions/Top USG-funded global health R&D institutions: Authors' analysis of USG investment data from the G-FINDER survey, including funding for R&D for neglected diseases from 2007–2015 and for Ebola and select viral hemorrhagic fevers from 2014–2015. Reflects USG funding received by entities in state including academic and research institutions, product development partnerships, other nonprofits, select corporations, and government research institutions, as well as self-funding or other federal agency transfers received by federal agencies located in state; but excludes pharmaceutical industry data which is aggregated and anonymized in the survey for confidentiality purposes. See methodology for additional details.
  • Jobs created: Based on previous analysis of the economic impact of National Institutes of Health R&D funding and author's analysis described above. See methodology for additional details.
  • Case study photo: PATH/Minzayar
Close